EYE TECH CARE receives CFDA Approval for its EyeOP1 glaucoma treatment product
Award-winning medical technology company EYE TECH CARE has received approval from the China Food and Drug Administration (CFDA) to begin marketing its EyeOP1® glaucoma treatment product in China.
Glaucoma affects 120 million people globally and is the second most common cause of blindness after cataract. China has the largest population affected by glaucoma with 22 million patients, a number growing at an average rate of 7.5 percent per year according to Market Scope.
The key benefits to using high-intensity ultrasound technology include:
- Totally non-invasive approach minimizes risks associated with other traditional option.
- A standardized and quick procedure that takes less than three minutes
- Short learning curve, high reproducibiity, light clinical follow-up